🟢 INCY trading 4.4% up today, fueled by strong Q1 earnings and recent CMS settlement

INCY is trading at $109.00 (up 4.4%) in pre-market, continuing its rebound from last week's selloff.

• The company reported a strong Q1 2026 earnings beat on April 28, 2026, surpassing analyst estimates for both EPS and revenue.
• Recent positive momentum is also driven by a significant non-cash benefit of $246 million expected in Q2 2026, following a June 22, 2026, settlement with CMS regarding Opzelura.
• Investors are also buoyed by positive data from its late-stage pipeline, including results presented at EHA 2026.